Welcome to our dedicated page for Wellbeing Digital Sciences news (Ticker: KONEF), a resource for investors and traders seeking the latest updates and insights on Wellbeing Digital Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wellbeing Digital Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wellbeing Digital Sciences's position in the market.
Wellbeing Digital Sciences Inc. announced that its subsidiary, KGK Sciences Inc., has successfully guided client Hofseth Biocare ASA in notifying the FDA regarding its ProGo® Bioactive Peptides, receiving a No Objection Acknowledgment (AKL) letter. This recognition places HBC on a short list of companies with FDA-approved New Dietary Ingredients. The AKL letter signifies the highest safety rating for HBC's dietary ingredient, following similar accolades for its other products. This achievement reiterates KGK's expertise in regulatory guidance in the nutraceutical industry.
Wellbeing Digital Sciences Inc. (OTC: KONEF) updates shareholders on its progress. As of June, its subsidiary KGK Sciences Inc. has projected future revenues of
Wellbeing Digital Sciences Inc. (OTC: KONEF) has announced a shift in its financial year-end from July 31 to October 31. This change, requested by the Company's auditors, aims to enhance the efficiency of annual audited financial statement production. Consequently, the organization will undergo a transitional 15-month financial year ending in October 2022. Further details regarding this change will be accessible in the Company's Notice of Change of Financial Year-End, which will be filed on SEDAR.
Wellbeing Digital Sciences announced that its subsidiary KGK Sciences will conduct a Phase II clinical trial to test the efficacy of psilocybin for treating treatment-resistant PTSD. This collaboration with Halucenex Life Sciences aims to develop innovative clinical solutions in mental healthcare. KGK, a leading contract research organization, will manage various research services including clinical trial protocol development and data analysis. This partnership signifies a notable step towards alternative treatment solutions.
Wellbeing Digital Sciences Inc. has appointed Natalie Dolphin as the new Vice President of Marketing and Investment Relations. With over 15 years of experience, Dolphin aims to enhance the company’s marketing and investment strategies. Previously, she held key roles at the Canadian Securities Exchange and MagicMed Industries. CEO Najla Guthrie praised Dolphin’s ability to lead effective marketing initiatives. The company, focused on evidence-based mental healthcare solutions, plans to leverage Dolphin’s expertise to expand its clinical network and improve its market presence.
Wellbeing Digital Sciences, trading under OTC symbol KONEF, has reported successful clinical trial results for its natural health product, GJ 191 (marketed as JointAlive®), in treating knee osteoarthritis. Conducted by KGK Sciences, participants taking GJ 191 experienced significant reductions in knee pain and improved joint function at 6 and 12 weeks, compared to a placebo group. Notably, 53% of GJ 191 users reported clinically meaningful improvements versus 38% in the placebo group. This product has received FDA notification as a New Dietary Ingredient, marking a step forward in natural health solutions for joint health.
Wellbeing Digital Sciences Inc. (OTC: KONEF) reported its financial results for the nine-month period ending April 30, 2022, with revenue at $5,280,640, compared to $0 in the prior year. However, the net loss rose significantly to $21,149,109 from $4,905,255, largely due to increased share-based payments and operational costs. The company aims to enhance its leadership team and evaluate strategic opportunities. Despite promising growth in revenue, the rising net loss poses concerns for investors looking for stability in financial performance.
Wellbeing Digital Sciences (OTC: KONEF) announced positive results from a clinical study by its subsidiary KGK Science on the GJ 191 supplementation, known as JointAlive®, aimed at treating osteoarthritis. The randomized, double-blind study showed that participants taking GJ 191 experienced significant reductions in knee pain and improved joint function compared to the placebo group. Specifically, 53% of those on GJ 191 reported clinically meaningful improvements after 12 weeks. This formulation, based on Traditional Chinese Medicine, has been notified to the FDA as a New Dietary Ingredient.
Wellbeing Digital Sciences Inc. has appointed Terry Zimaro as Chief Financial Officer, enhancing its leadership team. With over 20 years of experience in finance, particularly in high-growth sectors including psychedelics, Zimaro aims to drive profitability and operational efficiency. His appointment comes at a crucial juncture for the company, which focuses on innovative mental healthcare solutions, including psychedelic medicine and digital therapeutics. CEO Najla Guthrie expressed confidence in Zimaro's ability to impact the company’s corporate strategy and growth opportunities.
FAQ
What is the current stock price of Wellbeing Digital Sciences (KONEF)?
What is the market cap of Wellbeing Digital Sciences (KONEF)?
